cas 441797-42-8|| where to buy N-[5-(4-Bromophenyl)-6-chloro-4-pyrimidinyl]-N'-(phenylmethyl)sulfamide

Product Name:N-[5-(4-Bromophenyl)-6-chloro-4-pyrimidinyl]-N'-(phenylmethyl)sulfamide

IUPAC Name:benzyl({[5-(4-bromophenyl)-6-chloropyrimidin-4-yl]sulfamoyl})amine

: CAS：441797-42-8; Molecular Formula：C17H14BrClN4O2S; Purity：95%+

Packing Unit	Available Stock	Price($)
CM337693-100mg	in stock	ƐƐƴ
CM337693-250mg	in stock	ƴƴȖ
CM337693-1g	in stock	ŪŪǑ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 441797-42-8 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:441797-42-8; Molecular Formula:C17H14BrClN4O2S; Melting Point:-; Smiles Code:O=S(NCC1=CC=CC=C1)(NC2=NC=NC(Cl)=C2C3=CC=C(Br)C=C3)=O; Density:

: Catalog Number:CM337693; Molecular Weight:453.74; Boiling Point:; MDL No:; Storage:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Aprocitentan; New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023.
Aprocitentan is an investigational, novel, oral, dual endothelin receptor antagonist (ERA), which potently inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan has a low potential for drug-drug interaction and a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.
A new drug application (NDA) for aprocitentan was accepted for review by the US FDA.